Stay updated on Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    A site-wide notice links to updates and FAQs about NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology under Executive Order 14434.
    Difference
    1%
    Check dated 2026-10-26T16:46:57.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer now displays site revision v3.7.2 instead of v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-19T21:59:28.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The site revision label changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-13T04:26:45.000Z thumbnail image
  4. Check
    31 days ago
    Change Detected
    Summary
    A 403 Forbidden error page is now shown when accessing the study record, replacing the previous content. The page includes a 403 message and a Home link, indicating access is denied rather than study details.
    Difference
    0.5%
    Check dated 2026-09-28T22:42:35.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study content with an access-denied message. The header and navigation remain visible while the study details are no longer accessible, indicating an access issue rather than new content.
    Difference
    18%
    Check dated 2026-09-21T22:50:36.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    The study page now lists related topics: Lung cancer and MedlinePlus Genetics. This improves access to disease- and genetics-related resources from the study record.
    Difference
    0.2%
    Check dated 2026-09-14T19:50:38.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.